Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2005 Nov 1;23(31):8057-64.
doi: 10.1200/JCO.2005.02.0958.

Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial

Kazuo Koyanagi  1 , Steven J O'Day, Rene Gonzalez, Karl Lewis, William A Robinson, Thomas T Amatruda, He-Jing Wang, Robert M Elashoff, Hiroya Takeuchi, Naoyuki Umetani, Dave S B Hoon
Affiliations
Multicenter Study

Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial

Kazuo Koyanagi et al. J Clin Oncol. .

Abstract

Purpose: Circulating tumor cells (CTCs) in blood may be important in assessing tumor progression and treatment response. We hypothesized that quantitative real-time reverse transcriptase polymerase chain reaction using multimarker mRNA assays could detect CTCs and be used as a surrogate predictor of outcome in patients receiving neoadjuvant biochemotherapy (BC) for melanoma.

Patients and methods: Blood specimens were collected at four sampling points from 63 patients enrolled on a prospective multicenter phase II trial of BC before and after surgical treatment of American Joint Committee on Cancer stage III melanoma. Each specimen was assessed by quantitative real-time reverse transcriptase polymerase chain reaction for expression of four melanoma-associated markers: melanoma antigen recognized by T cells 1; beta1 --> 4-N-acetylgalactosaminyltransferase; paired box homeotic gene transcription factor 3; and melanoma antigen gene-A3 family, and the changes of CTCs during treatment and prognostic effect of CTCs after overall treatment on recurrence and survival were investigated.

Results: At a median postoperative follow-up time of 30.4 months, 44 (70%) patients were clinically disease free. In relapse-free patients, the number of detected markers significantly decreased during preoperative BC (P = .036), during postoperative BC (P = .002), and during overall treatment (P < .0001). Marker detection after overall treatment was associated with significant decreases in relapse-free and overall survival (P < .0001). By multivariate analysis using a Cox proportional-hazards model, the number of markers detected after overall treatment was a significant independent prognostic factor for overall survival (risk ratio, 12.6; 95% CI, 3.16 to 50.5; P = .0003).

Conclusion: Serial monitoring of CTCs in blood may be useful for indicating systemic subclinical disease and predicting outcome of patients receiving neoadjuvant BC for metastatic melanoma.

PubMed Disclaimer

Conflict of interest statement

Authors’ Disclosures of Potential Conflicts of Interest

Although all authors completed the disclosure declaration, the following authors or their immediate family members indicated a financial interest. No conflict exists for drugs or devices used in a study if they are not being evaluated as part of the investigation. For a detailed description of the disclosure categories, or for more information about ASCO’s conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.

[Table: see text]

Figures

Fig 1
Fig 1
Copy levels of individual mRNA markers in blood specimens obtained before, during, and after treatment. The relative mRNA copy number of each marker after treatment was significantly lower than its copy number before treatment: melanoma antigen recognized by T cells 1 (MART-1), P = .0006; β1 → 4-N-acetylgalactosaminyltransferase (GalNAc-T), P = .005; paired box homeotic gene transcription factor 3 (PAX-3), P = .002; melanoma antigen gene-A3 family (MAGE-A3), P = .013. Bars indicate mean copy numbers.
Fig 2
Fig 2
Kaplan-Meier curves of relapse-free survival based on marker detection after treatment.
Fig 3
Fig 3
Kaplan-Meier curves of overall survival based on marker detection after treatment.
See this image and copyright information in PMC

References

    1. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–3648. - PubMed
    1. Greene FL, Page DL, Fleming ID, et al., editors. AJCC Cancer Staging Manual. 6. New York, NY: Springer-Verlag; 2002.
    1. O’Day SJ, Gammon G, Boasberg PD, et al. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol. 1999;17:2752–2761. - PubMed
    1. Richards JM, Gale D, Mehta N, et al. Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of meta-static melanoma. J Clin Oncol. 1999;17:651–657. - PubMed
    1. Gibbs P, Iannucci A, Becker M, et al. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma. Melanoma Res. 2000;10:171–179. - PubMed

Publication types

MeSH terms